Thyrocare Technologies Limited announced its unaudited financial results for Q1FY27 (quarter ended June 30, 2026) through a regulatory filing under SEBI Regulation 30. The company reported strong financial performance with significant year-on-year growth across key metrics.

Financial Performance Highlights

Consolidated Results:

  • Revenue from operations: ₹240.02 crore in Q1FY27, representing 24.3% YoY growth from ₹193.03 crore in Q1FY26
  • Gross margin: ₹177.86 crore, up 29.4% YoY from ₹137.40 crore
  • Gross margin percentage: 74.1% in Q1FY27 vs 71.2% in Q1FY26
  • EBITDA: ₹77.27 crore, up 33.8% YoY from ₹57.77 crore
  • EBITDA margin: 32.2% in Q1FY27 vs 29.9% in Q1FY26
  • Profit After Tax (PAT): ₹51.33 crore, up 34.1% YoY from ₹38.29 crore
  • PAT margin: 21.4% in Q1FY27 vs 19.8% in Q1FY26
  • EPS: ₹3.23, up 34.0% YoY from ₹2.41

Cost Structure:

  • Cost of materials consumed/sold: ₹62.16 crore
  • Employee benefit expenses: ₹39.61 crore
  • Other expenses: ₹60.98 crore
  • Depreciation and amortization: ₹12.49 crore
  • Finance cost: ₹1.35 crore
  • Other income: ₹4.15 crore
  • Tax expenses: ₹16.96 crore

Operational Highlights

  • Processed 55.2 million tests in Q1FY27, representing 28% YoY growth
  • Maintained position as India's largest diagnostic test volume processor
  • Pathology segment grew 26% YoY, with franchise revenue up 27% and partnership revenue up 26%
  • Achieved Six Sigma quality standards with complaints reduced to 3.1 per million tests (down 24% YoY)
  • Average Turnaround Time (ATAT) maintained at 3.37 hours from sample receipt
  • India's first diagnostic chain to achieve this benchmark

Strategic Business Development

  • Expanded into Specialty Diagnostics, marking next growth phase
  • Commenced specialty journey with Allergy and Genomics testing
  • Progressively expanding specialty test portfolio with focus on building clinical trust
  • Focus on scientific rigor, uncompromising quality, and industry-leading turnaround times

Management Commentary

Rahul Guha, MD & CEO, stated: "Thyrocare reported a strong performance this quarter, driven by continued focus on operational efficiency, network expansion, and value-driven diagnostics. During the period, we also strengthened our specialty portfolio with the addition of allergy testing and entry into genomics through the launch of NIPT, with a phased expansion of the test menu underway. Thyrocare continues to expand its reach in underserved regions and scale its franchise and partner network, while remaining committed to delivering high-quality, affordable healthcare services across India."

Company Background

Thyrocare Technologies Limited (NSE: THYROCARE, BSE: 539871) is India's first advanced fully automated laboratory chain with pan-India presence. The company focuses on providing quality and affordable diagnostic services to patients, healthtech providers, insurance companies, pharmaceutical companies, franchisees, laboratories, hospitals, and government.

Network and Scale

  • Extensive network of laboratories across PAN India
  • Quarterly active franchise count: ~11,700
  • Processed 55.2 million diagnostic and screening investigations in Q1FY27
  • Quality accreditations include ISO 9001:2015, NABL, and CAP accreditations

Comparative Performance

Quarterly Comparison:

  • Revenue: Q1FY27 ₹240.02 Cr vs Q4FY26 ₹223.95 Cr vs Q1FY26 ₹193.03 Cr
  • EBITDA: Q1FY27 ₹77.27 Cr vs Q4FY26 ₹75.09 Cr vs Q1FY26 ₹57.77 Cr
  • PAT: Q1FY27 ₹51.33 Cr vs Q4FY26 ₹48.70 Cr vs Q1FY26 ₹38.29 Cr

Annual Reference (FY26):

  • Revenue: ₹829.04 crore
  • PAT: ₹162.85 crore
  • EPS: ₹10.27